WuXi Biologics (Cayman) (FRA:1FW2) EPS (Basic) : €0.11 (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) EPS (Basic)?

WuXi Biologics (Cayman)'s basic earnings per share (Basic EPS) for the six months ended in Dec. 2023 was €0.04. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.11.

WuXi Biologics (Cayman)'s EPS (Diluted) for the six months ended in Dec. 2023 was €0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.10.

WuXi Biologics (Cayman)'s EPS without NRI for the six months ended in Dec. 2023 was €0.05. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was 0.14.

During the past 12 months, WuXi Biologics (Cayman)'s average EPS without NRIGrowth Rate was -8.20% per year. During the past 3 years, the average EPS without NRI Growth Rate was 33.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 45.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, WuXi Biologics (Cayman)'s highest 3-Year average EPS without NRI Growth Rate was 138.10% per year. The lowest was 33.60% per year. And the median was 57.20% per year.

WuXi Biologics (Cayman) EPS (Basic) Historical Data

The historical data trend for WuXi Biologics (Cayman)'s EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) EPS (Basic) Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

0.04

0.05

0.11

0.14

0.11

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Basic)	Get a 7-Day Free Trial													0.05	0.09	0.06	0.07	0.04

WuXi Biologics (Cayman) EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

WuXi Biologics (Cayman)'s Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(436.62	-	0)	/	4163.543
	=	0.10

WuXi Biologics (Cayman)'s Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(145.516	-	0)	/	4168.998
	=	0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.11

WuXi Biologics (Cayman) (FRA:1FW2) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

WuXi Biologics (Cayman) EPS (Basic) Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

WXIBF:USA WXXWY:USA 2269:Mexico 02269:Hong Kong 1FW1:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines